Open AccessImmunohistochemical analysis of O6-methylguanine-DNA methyltransferase (MGMT) protein expression as prognostic marker in glioblastoma patients treated with radiation therapy with concomitant and adjuvant Temozolomide
Author(s) -
Samar Galal Younis,
Rasha Abd El-Ghany Khedr,
Safinaz H. El-Shorbagy
Publication year - 2015
Publication title -
journal of the egyptian national cancer institute
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.398
H-Index - 22
eISSN - 2589-0409
pISSN - 1110-0362
DOI - 10.1016/j.jnci.2015.11.003
Subject(s) - temozolomide , medicine , concomitant , oncology , radiation therapy , immunohistochemistry , methyltransferase , chemotherapy , adjuvant , adjuvant therapy , predictive marker , pathology , cancer , gene , biochemistry , methylation , chemistry
O6-methylguanine-DNA methyltransferase (MGMT) protein expression using immunohistochemical analysis was proposed as a prognostic marker for patients with newly diagnosed glioblastoma (GBM) treated with radiation therapy with concurrent and adjuvant Temozolomide (TMZ).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom